Molecular Partners AG (MOLN)
5.42
+0.22
(+4.23%)
USD |
NASDAQ |
Nov 21, 16:00
5.71
+0.29
(+5.35%)
After-Hours: 07:43
Molecular Partners Enterprise Value: 28.94M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 28.94M |
| November 20, 2024 | 20.83M |
| November 19, 2024 | 30.42M |
| November 18, 2024 | 44.05M |
| November 15, 2024 | 25.63M |
| November 14, 2024 | 22.68M |
| November 13, 2024 | 32.26M |
| November 12, 2024 | 38.88M |
| November 11, 2024 | 43.62M |
| November 08, 2024 | 57.68M |
| November 07, 2024 | 51.41M |
| November 06, 2024 | 59.15M |
| November 05, 2024 | 41.10M |
| November 04, 2024 | 52.39M |
| November 01, 2024 | 54.73M |
| October 31, 2024 | 26.73M |
| October 30, 2024 | 55.83M |
| October 29, 2024 | 57.68M |
| October 28, 2024 | 43.72M |
| October 25, 2024 | 44.72M |
| October 24, 2024 | 29.11M |
| October 23, 2024 | 17.48M |
| October 22, 2024 | 47.37M |
| October 21, 2024 | 54.34M |
| October 18, 2024 | -9.059M |
| Date | Value |
|---|---|
| October 17, 2024 | -5.408M |
| October 16, 2024 | -6.404M |
| October 15, 2024 | -6.404M |
| October 14, 2024 | -13.04M |
| October 11, 2024 | -13.04M |
| October 10, 2024 | -13.04M |
| October 09, 2024 | -7.858M |
| October 08, 2024 | -7.858M |
| October 07, 2024 | -12.71M |
| October 04, 2024 | -4.080M |
| October 03, 2024 | -18.69M |
| October 02, 2024 | -17.03M |
| October 01, 2024 | -11.71M |
| September 30, 2024 | -1.853M |
| September 27, 2024 | -8.723M |
| September 26, 2024 | -21.34M |
| September 25, 2024 | -23.66M |
| September 24, 2024 | -10.54M |
| September 23, 2024 | -20.01M |
| September 20, 2024 | -22.00M |
| September 19, 2024 | -22.00M |
| September 18, 2024 | -16.36M |
| September 17, 2024 | -8.391M |
| September 16, 2024 | -4.076M |
| September 13, 2024 | -3.744M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-127.57M
Minimum
May 11 2022
884.52M
Maximum
Jan 14 2022
79.86M
Average
-39.50M
Median
Jun 02 2023
Enterprise Value Benchmarks
| AC Immune SA | 137.84M |
| CRISPR Therapeutics AG | 2.015B |
| Addex Therapeutics Ltd | 4.450M |
| NLS Pharmaceutics Ltd | 14.00M |
| MoonLake Immunotherapeutics | 2.784B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.97M |
| Revenue (Quarterly) | 0.7875M |
| Total Expenses (Quarterly) | 17.66M |
| EPS Diluted (Quarterly) | -0.5666 |
| Profit Margin (Quarterly) | -2.41K% |
| Earnings Yield | -39.51% |
| Normalized Earnings Yield | -37.39 |